Interleukin-6 overexpression induces pulmonary hypertension

Circulation Research

Volumn 104, Issue 2, 2009, Pages 236-244

  Steiner, M Kathryn ^a,c   Syrkina, Olga L ^a   Kolliputi, Narasaish ^a   Mark, Eugene J ^b   Hales, Charles A ^a   Waxman, Aaron B ^a  

^a Pulmonary Critical Care Unit

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Interleukin 6; Proliferation; Pulmonary artery hypertension

Indexed keywords

ANGIOGENIC FACTOR; BLOOD CLOTTING FACTOR 5A; INTERLEUKIN 6; MAX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN BCL 2; SURVIVIN; VASCULOTROPIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BCL2 PROTEIN, MOUSE; MAX PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; MYC PROTEIN, MOUSE; ONCOPROTEIN; SURVIVIN PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HUMAN; HYPOXIA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ANOXIA; APOPTOSIS; ARTERIOLE; BLOOD PRESSURE; C57BL MOUSE; CELL PROLIFERATION; CHRONIC DISEASE; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HYPERPLASIA; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; TIME; UPREGULATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANOXIA; APOPTOSIS; ARTERIOLES; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOOD PRESSURE; CELL PROLIFERATION; CHRONIC DISEASE; ENDOTHELIAL CELLS; HYPERPLASIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PULMONARY ARTERY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 59849118025     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.182014     Document Type: Article

References (49)

1. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43:25S-32S.
2. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-{beta}1 and bone morpho-genetic proteins. Circulation. 2001;104:790-795.
3. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med. 2002;8:987-994.
4. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479-1491.
5. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285.
6. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628-1631.
7. Katsushi H, Kazufumi N, Hideki F, Katsumasa M, Hiroshi M, Kengo K, Hiroshi D, Nobuyoshi S, Tetsuro E, Hiromi M, Tohru O. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoat-tractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004;68:227-231.
8. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195:367-374.
9. Yoshio T, Masuyama JI, Kohda N, Hirata D, Sato H, Iwamoto M, Mimori A, Takeda A, Minota S, Kano S. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol. 1997;24:489-495.
10. Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, Viard JP, Wechsler B, Gherardi R. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med. 1998;157:907-911.
11. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M, Yokohari R. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol. 1999;26:2357-2362.
12. Parravinci C, Corbellino M, Paulli M, Magrini U, Lazzarino M, Moore PS, Chang Y. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol. 1997;151: 1517-1522.
13. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-2512.
14. DiCosmo BF, Geba GP, Picarella D, Elias JA, Rankin JA, Stripp BR, Whitsett JA, Flavell RA. Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. J Clin Invest. 1994;94:2028-2035.
15. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15:427-438.
16. Wang GS, Qian GS, Mao BL, Cai WQ, Chen WZ, Chen Y. [Changes of interleukin-6 and Janus kinases in rats with hypoxic pulmonary hypertension]. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:664-667.
17. Kubo K, Hanaoka M, Hayano T, Miyahara T, Hachiya T, Hayasaka M, Koizumi T, Fujimoto K, Kobayashi T, Honda T. Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema. Respir Physiol. 1998;111:301-310.
18. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest. 2005;128:572S-573S.
19. Kasahara Y, Kimura H, Kurosu K, Sugito K, Mukaida N, Matsushima K, Kuriyama T. MCAF/MCP-1 protein expression in a rat model for pulmonary hypertension induced by monocrotaline. Chest. 1998;114(1 suppl):67S.
20. Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN. Trip-tolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2000;162:2252-2258.
21. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med. 2007;175:1280-1289.
22. Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol. 1995;108:287-291.
23. Savale L, Izikki M, Tu L, Rideau D, Raffestin B, Naitre B, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the interleukin-6 gene. Am J Respir Crit Care Med. 2007;175:A42.
24. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94:1109-1114.
25. Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res. 2005;97: 596-604.
26. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hyp-oxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007;292:L885-L897.
27. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup V, Hogaboam C, Taraseviciene-Stewart L, Voelkel N, Rabinovitch M, Grunig E, Grunig G. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205:361-372.
28. Rai PR, Cool C, King J, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer Paradigm of severe angioproliferative pulmonary hypertension. Am J Respir Crit Care Medicine. 2008;178:558-564.
29. Wagenvoort C, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation. 1970;42:1163-1184.
30. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension. Vascular structure, mor-phometry, and responsiveness to vasodilator agents. Circulation. 1989; 80:1207-1221.
31. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol. 1997;151:1019-1025.
32. Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD. Angioten-sin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med. 1998;158:939-950.
33. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation. 2005;111: 2988-2996.
34. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambart-sumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164: 253-262.
35. Lagna G, Nguyen PH, Ni W, Hata A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006;291: L1059-L1067.
36. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;285:L740-L754.
37. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S. (Pubitemid 38759713)
38. Eccleston-Joyner CA, Gray SD. Arterial hypertrophy in the fetal and neonatal spontaneously hypertensive rat. Hypertension. 1988;12: 513-518.
39. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis. 1992;145: 793-797.
40. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28:434-442.
41. Yao JS, Zhai W, Fan Y, Lawton MT, Barbaro NM, Young WL, Yang GY. Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells. J Cereb Blood Flow Metab. 2007;27:510-520.
42. Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Tatsumi K, Kuriyama T, Voelkel NF. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J. 2007;21:3640-3652.
43. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170: 1340-1348.
44. Yeager ME, Golpon HA, Voelkel NF, Tuder RM. Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest. 2002;121(3 suppl):61S.
45. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1473-L1479.
46. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005;96: 1053-1063.
47. Waxman AB, Mahboubi K, Knickelbein RG, Mantell LL, Manzo N, Pober JS, Elias JA. Interleukin-11 and interleukin-6 protect cultured human endothelial cells from H2O2-induced cell death. Am J Respir Cell Mol Biol. 2003;29:513-522.
48. Shi W, Chen H, Sun J, Chen C, Zhao J, Wang YL, Anderson KD, Warburton D. Overexpression of Smurf1 negatively regulates mouse embryonic lung branching morphogenesis by specifically reducing Smad1 and Smad5 proteins. Am J Physiol Lung Cell Mol Physiol. 2004; 286:L293-L300.
49. Chen HB, Shen J, Ip YT, Xu L. Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev. 2006;20:648-653.